SEC Form 4

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	irden
hours per response:	0.5

Instruction 1(b)									
(_)			Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940		<u> </u>				
1. Name and Addr		g Person [*]	2. Issuer Name and Ticker or Trading Symbol Jazz Pharmaceuticals plc [JAZZ]		tionship of Reportir all applicable)	Reporting Person(s) to Issuer le)			
Smith Mark	Douglas			X	Director	10% Owner			
(Last) 5TH FL, WATH	(First) ERLOO EXC	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/29/2021	/Day/Year) Officer (give title below)					
WATERLOO R	RD								
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/Group Filing (Check Applicable				
(Street)				X	Form filed by One	e Reporting Person			
DUBLIN 4	L2				Form filed by Mo Person	re than One Reporting			
(City)	(State)	(Zip)							
		Table I - Non-De	rivative Securities Acquired, Disposed of, or Bene	eficially	Owned				

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (l 8)	ction				5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Ordinary Shares	07/29/2021		A ⁽¹⁾		2,246	Α	\$ <mark>0.0</mark>	4,836	D	

									-						
		Tal	ble II - Derivat (e.g., pı					iired, Disp options, d					d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deriv Secu Acqu (A) o Dispo of (D	r osed) r. 3, 4	nber 6. Date Exercisable and Expiration Date (Month/Day/Year) sed 3, 4		and 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022.

<u>By: /s/Adam Guttmann, as</u>	
attorney in fact For: Mark D.	08/02/2021
Smith	
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.